Brought to you by 
Avalon licenses Compugen's Gencarta
10 Jul 2001
Executive Summary
Avalon Pharmaceuticals (cancer drugs) has licensed Compugen's (drug discovery technology) Gencarta genome, transcriptome, and proteome database and query tools. The companies will also collaborate on identifying and developing drug targets and diagnostic markers from genomic and expressed data for Avalon.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Avalon licenses Compugen's Gencarta
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice